Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 5Gastrointestinal 4Genitourinary 3Thoracic 2Sarcoma 1Head & Neck 1Gynecologic 1

Conditions

Neoplasms 1Melanoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × sotigalimab × Thoracic × Clear all
NCT03502330 2024-07-03

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Yale University

Phase 1 Completed
42 enrolled 17 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT03123783 2023-12-26

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Apexigen America, Inc.

Phase 1/2 Completed
140 enrolled 16 charts
DermatologicThoracic

Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡